Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. News
  7. Summary
    ALKS   IE00B56GVS15

ALKERMES PLC

(ALKS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alkermes : schizophrenia drug gets U.S. FDA nod

06/01/2021 | 07:08am EDT

June 1 (Reuters) - Alkermes Plc said on Tuesday the U.S. Food and Drug Administration (FDA) approved its drug Lybalvi to treat schizophrenia and bipolar I disorder.

The company expects to commercially launch the drug in the fourth quarter. (Reporting by Dania Nadeem in Bengaluru; Editing by Aditya Soni)


ę Reuters 2021
All news about ALKERMES PLC
09:50aALKERMES : Reports Earnings, Revenue Increase for Q2, Raises Full-Year Guidance
MT
09:18aALKERMES : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
07:54aALKERMES : Q2 2021 Earnings slides Final 7 27 21 607pm.pdf
PU
07:30aALKERMES : Q2 Earnings Snapshot
AQ
07:14aALKERMES : Reports Second Quarter 2021 Financial Results (Form 8-K)
PU
07:07aALKERMES PLC. : Results of Operations and Financial Condition (form 8-K)
AQ
07:06aGUIDANCE : (ALKS) ALKERMES Forecasts Fiscal Year 2021 EPS Range $0.52 - $0.70
MT
07:05aALKERMES : Earnings Flash (ALKS) ALKERMES Reports Q2 EPS $0.30, vs. Street Est o..
MT
07:05aALKERMES : Earnings Flash (ALKS) ALKERMES Posts Q2 Revenue $10M, vs. Street Est ..
MT
07/26ALKERMES : Announces Recipients of 2021 Alkermes Inspiration Grants Program
AQ
More news
Financials (USD)
Sales 2021 1 154 M - -
Net income 2021 -82,1 M - -
Net cash 2021 391 M - -
P/E ratio 2021 -44,8x
Yield 2021 -
Capitalization 4 158 M 4 158 M -
EV / Sales 2021 3,26x
EV / Sales 2022 2,95x
Nbr of Employees 2 245
Free-Float 96,7%
Chart ALKERMES PLC
Duration : Period :
Alkermes plc Technical Analysis Chart | ALKS | IE00B56GVS15 | MarketScreener
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 25,77 $
Average target price 23,89 $
Spread / Average Target -7,30%
EPS Revisions
Managers and Directors
Richard F. Pops Chairman & Chief Executive Officer
Iain Michael Brown Senior VP, Chief Financial & Accounting Officer
Craig C. Hopkinson Chief Medical Officer & EVP-Research & Development
Thomas Harvey Chief Information Officer & Senior VP-IT
Sondra Smyrnios Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALKERMES PLC29.17%3 873
MODERNA, INC.214.44%131 902
LONZA GROUP AG20.01%55 520
IQVIA HOLDINGS INC.35.73%46 608
CELLTRION, INC.-27.16%31 131
SEAGEN INC.-17.54%26 209